ET-traps-a Novel Therapeutic for Treatment of Neurological Disorders

Different neurodegenerative disorders affect millions of people around the world and currently there is no cure for them. Certain neurodegenerative conditions are associated with pathologically elevated Endothelin (ET)-1 levels. There are currently various drugs in use to block the ET system, but these are associated with various side effects. In this paper, the potential use of ET-traps is discussed, which provide a potent way of lowering the pathologically elevated ET-1 levels found in these different neurodegenerative disorders and are non-toxic for use.

Keywords: Endothelin-1; ET-traps; Neurodegenerative disorders; Multiple sclerosis; Alzheimer’s disease; Parkinson’s disease; Amyotrophic lateral sclerosis

Abbreviations: Amyloid Beta; AD: Alzheimer’s Disease; ALS: Amyotrophic Lateral Sclerosis; ET-1: Endothelin-1; BBB: Blood Brain Barrier; CBF: Cerebral blood flow; MS: Multiple Sclerosis; PD: Parkinson’s Disease